This study is just one of several published over the last few years that has found a significant increased risk of bladder cancer among Actos patients.
New York, New York (PRWEB) February 18, 2013
As Actos lawsuits continue to mount, a new study published in the British Diabetic Association journal, “Diabetic Medicine,” has confirmed an association between Actos and bladder cancer, Bernstein Liebhard LLP reports. The analysis of six separate Actos studies included data on a total of 215,142 Actos users who were followed for an average of 44 months. According to the study, the risk of bladder cancer was significantly higher in patients using Actos compared with control groups.*
“This study is just one of several published over the last few years that has found a significant increased risk of bladder cancer among Actos patients,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm is currently offering free Actos bladder cancer lawsuit evaluations to individuals who may have been harmed by the medication.
Actos Bladder Cancer Lawsuits
Actos, known generically as pioglitazone, is approved as a treatment for type 2 diabetes. The U.S. Food & Drug Administration (FDA) ordered Takeda to add new warnings to the Actos label in June 2011, after a study found that long-term use of the drug increased the risk for bladder cancer.** Other studies that have confirmed this association include research published last May in the British Medical Journal which concluded that taking the drug for two years can double the risk of developing bladder cancer. *** A second study published in the Canadian Medical Association Journal in July 2012 found that patients taking Actos face a 22 percent increased risk of developing bladder cancer. ****
While Actos is still available in the U.S., the drug has been pulled from the market in Germany and France due to its association with bladder cancer. At the time of the FDA alert, Actos was the best-selling diabetes drug in the world, and some experts have speculated that Takeda Pharmaceuticals could eventually face as many as 10,000 Actos bladder cancer lawsuits. *****
Hundreds of Actos bladder cancer lawsuits have been filed in a multidistrict litigation underway in the U.S. District Court, Western District of Louisiana. Court records indicate that the first trial in the federal Actos litigation is scheduled to begin in November 2014, followed by the second trial in July 2015. (In re: Actos Product Liability Litigation, MDL No. 2299)
Actos users who developed bladder cancer may be entitled to compensation for medical expenses, lost wages, pain and suffering, and more. Learn more about filing an Actos lawsuit by visiting Bernstein Liebhard LLP’s website, http://www.consumerinjurylawyers.com/. For additional information, contact a lawyer at Bernstein Liebhard LLP today at (877) 779-1414.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 10 consecutive years.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP